17:09 , Jun 15, 2017 |  BC Week In Review  |  Clinical News

Adaptimmune starts Phase I of T cell therapy plus Keytruda

Adaptimmune Therapeutics plc (NASDAQ:ADAP) began a Phase I trial of NY-ESO SPEAR T-cell therapy (ADAP NY-ESO TCR, GSK3377794) plus Keytruda pembrolizumab to treat multiple myeloma (MM). The open-label, U.S. trial will evaluate safety in up...
07:00 , Oct 24, 2013 |  BC Innovations  |  Strategy

Driving CAR-based cellular therapies

Adoptive T cell therapies were first developed in the mid-1980s but only recently entered the limelight owing to dramatic clinical results achieved with the latest incarnation, chimeric antigen receptor-based cell therapies. Novartis AG 's 2012...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Clinical News

Enhanced TCR Therapy: Phase I/II started

Adaptimmune began an open-label, U.S. Phase I/IIa trial to evaluate enhanced TCR therapy in about 6 patients with the human leukocyte antigen serotype A201 (HLA-A201) allele and whose tumors express NY-ESO-1 and LAGE1. The company...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

Enhanced TCR Therapy for MM: Preliminary Phase I/II data

Preliminary data from 13 evaluable MM patients in a single-arm, open-label, U.S. Phase I/II trial showed that enhanced TCR therapy given in conjunction with autologous stem cell transplantation led to an ORR of 77% at...
08:00 , Jan 7, 2002 |  BC Week In Review  |  Clinical News

NY-ESO-1 immunotherapy: Therion began a dose-ranging European Phase I trial of its NY-ESO-1 immunotherapy, which uses rV-NY-ESO-1 and rF-NY-ESO-2 in a prime-boo

Therion Biologics Corp., Cambridge, Mass.   Product: NY-ESO-1 immunotherapy   Business: Cancer   Therapeutic category: Immune stimulation   Target: NY-ESO-1-expressing tumor cells   Description: Recombinant vaccinia NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1)   Indication: Treat...